Literature DB >> 8301145

B cells process and present lupus autoantigens that initiate autoimmune T cell responses.

M J Mamula1, S Fatenejad, J Craft.   

Abstract

Antibodies against U small nuclear ribonucleoprotein (snRNP) particles are a common finding in the sera of humans with SLE and in certain strains of mice with murine lupus. It is likely that Th cells are important in amplifying this autoantibody response. The focus of this work was to investigate events that might initiate autoimmune B and T cell response in non-autoimmune mice to native snRNP particles. Mice that were immunized and boosted with native mouse snRNPs failed to produce any detectable specific anti-snRNP antibody or T cell responses, suggesting that these autoreactive cells were deleted from the repertoire or were anergic to stimulation with this self Ag. In contrast, immunization with native foreign (human) snRNPs elicited both T cells and cross-reactive anti-snRNP antibodies; the latter predominantly were directed toward the A protein of the U1 snRNP. When mice were immunized with human and mouse snRNPs together in adjuvant, T cells specific for mouse snRNPs could be elicited. The results of these experiments suggested that the mechanism of breaking T cell tolerance to self snRNPs was dependent on the ability of cross-reactive B cells to process and present these autoantigens. To address this hypothesis, B cells purified from mice immunized with recombinant human A protein were transferred into naive mice. Upon boosting with native mouse snRNPs, autoreactive CD4+ T cells specific for mouse Ags, and not cross-reactive with human snRNPs, were observed. These studies support a model of molecular mimicry whereby autoantigen-presenting B cells are generated by foreign cross-reactive determinants that can, in turn, elicit an autoimmune T cell response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301145

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

Review 1.  B cells: new ways to inhibit their function in rheumatoid arthritis.

Authors:  Robert H Carter
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 2.  B cell signalling as therapeutic target.

Authors:  R H Carter
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 3.  Therapeutic potential for blockade of the CD40 ligand, gp39.

Authors:  J E Buhlmann; R J Noelle
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

Review 4.  T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens.

Authors:  Syamal K Datta; Li Zhang; Luting Xu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

5.  Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease.

Authors:  K Skriner; W H Sommergruber; V Tremmel; I Fischer; A Barta; J S Smolen; G Steiner
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

6.  T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus.

Authors:  G Riemekasten; C Weiss; S Schneider; A Thiel; A Bruns; F Schumann; S Bläss; G-R Burmester; F Hiepe
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 7.  Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future.

Authors:  Noam Jacob; William Stohl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

8.  Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.

Authors:  Chuanlin Ding; Li Wang; Jose Marroquin; Jun Yan
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

9.  T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors.

Authors:  M Kuwana; T A Medsger; T M Wright
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 10.  B-cell-targeted therapies in systemic lupus erythematosus.

Authors:  Vera Sau-Fong Chan; Helen Hoi-Lun Tsang; Rachel Chun-Yee Tam; Liwei Lu; Chak-Sing Lau
Journal:  Cell Mol Immunol       Date:  2013-01-28       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.